Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB BSE: 539524 SECTOR: Hospital & Healthcare Services  136k   1k   302

1799.85
-10.35 (-0.57%)
NSE: 29 Mar 4:00 PM

Price Summary

Today's High

₹ 1816.6

Today's Low

₹ 1795.15

52 Week High

₹ 2870

52 Week Low

₹ 1762.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

15004.97 Cr.

Enterprise Value

14809.78 Cr.

No. of Shares

8.34 Cr.

P/E

52.5

P/B

9.32

Face Value

₹ 10

Div. Yield

0.67 %

Book Value (TTM)

₹  193.06

CASH

540.61 Cr.

DEBT

345.42 Cr.

Promoter Holding

55.05 %

EPS (TTM)

₹  34.28

Sales Growth

25.64%

ROE

26.5 %

ROCE

32.11%

Profit Growth

22.83 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 22 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.64%
3 Year17.15%
5 Year16.26%

Profit Growth

1 Year22.83%
3 Year20.75%
5 Year17.67%

ROE%

1 Year26.5%
3 Year25.37%
5 Year24.96%

ROCE %

1 Year32.11%
3 Year33.18%
5 Year34.3%

Debt/Equity

0.2434

Price to Cash Flow

35.4

Interest Cover Ratio

17.1043959896235

CFO/PAT (5 Yr. Avg.)

1.21138138207569

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 55.05 0
Sep 2022 55.05 0
Jun 2022 55.05 0
Mar 2022 55.23 0
Dec 2021 55.23 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 20.7459391889033% for the Past 3 years.
  • The company has shown a good revenue growth of 17.1457190787028% for the Past 3 years.
  • Company has been maintaining healthy ROE of 25.3651231756712% over the past 3 years.
  • Company has been maintaining healthy ROCE of 33.1791525532649% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 17.1043959896235.
  • The Company has been maintaining an effective average operating margins of 25.9200985852344% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -85.5210918285486 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.21138138207569.
  • The company has a high promoter holding of 55.05%.

 Limitations

  • The company is trading at a high PE of 52.5.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 422.5 414.9 439.3 466.9 428.4
Total Expenditure 323 310.1 329.9 336.7 324
Operating Profit 99.5 104.8 109.4 130.2 104.4
Other Income 11.3 12.9 18.8 7.6 8.6
Interest 8.7 11.1 7.7 10 8.3
Depreciation 18.9 21.5 18.8 21.4 20.6
Exceptional Items 0 0 0 0 0
Profit Before Tax 83.2 85.1 101.7 106.4 84.1
Tax 21.5 19.9 22.1 27.8 21.7
Profit After Tax 61.7 65.2 79.6 78.6 62.4
Adjusted EPS (Rs) 7.41 7.83 9.54 9.42 7.48

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 1024.04 1164.9 1273.6 1490.56 1872.71
Total Expenditure 767.94 882.1 945.79 1083.18 1362.49
Operating Profit 256.11 282.8 327.81 407.38 510.22
Other Income 31.51 46.49 57.61 51.27 53.02
Interest 0.82 0.74 14.66 14.83 28.53
Depreciation 31.05 36.18 68.01 69.78 75.31
Exceptional Items 0 0 0 0 0
Profit Before Tax 255.76 292.37 302.75 374.04 459.39
Tax 87.49 96.93 79.57 93.94 115.34
Net Profit 168.27 195.44 223.18 280.11 344.05
Adjusted EPS (Rs.) 20.19 23.45 26.78 33.61 41.28

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 83.33 83.34 83.35 83.35 83.35
Total Reserves 693.19 847.49 932.94 1133.74 1393.12
Borrowings 0 0 0 0 166.67
Other N/C liabilities -8.46 -19.86 68.18 76.83 90.95
Current liabilities 111.12 134.46 211.29 252.25 449.82
Total Liabilities 879.18 1045.43 1295.75 1546.16 2183.91
Assets
Net Block 172.54 172.96 296.53 300.07 370.13
Capital WIP 9.36 2.87 10.3 5.51 14.45
Intangible WIP 0 0 0.99 3.48 0
Investments 29.72 32.37 93.88 120.4 1069.04
Loans & Advances 14.61 16.24 18.43 23.87 24.2
Other N/C Assets 40.21 24.77 13.21 3.53 9.71
Current Assets 612.76 796.23 862.41 1089.3 696.39
Total Assets 879.18 1045.43 1295.75 1546.16 2183.91
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 255.76 292.37 302.75 374.04 459.39
Adjustment 17.3 8.85 45.84 59.1 87.19
Changes in Assets & Liabilities 7.86 9.66 12.57 37.33 -5.67
Tax Paid -91.53 -102.38 -89.17 -97.12 -117.11
Operating Cash Flow 189.38 208.5 271.99 373.36 423.81
Investing Cash Flow -165.9 -92.75 -19.47 -195.19 -448.5
Financing Cash Flow 12.93 -54.33 -187.22 -135.74 142.04
Net Cash Flow 36.41 61.43 65.3 42.42 117.34

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 55.23 55.23 55.05 55.05 55.05
arvind lal - 31.36 31.36 - -
arvind lal 31.69 - - 31.36 31.36
vandana lal 19.29 - - 19.12 19.12
vandana lal - 19.12 19.12 - -
archana lal - - - 2.39 2.39
archana lal erdmann 2.03 2.39 2.39 - -
anjaneya lal 2.03 - - 2.03 2.03
anjaneya lal - 2.03 2.03 - -
arvind lal - eskay... - - - 2.02 2.02
eskay house huf - - 2.02 - -
eskay house (huf) - 2.02 - - -
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 44.77 44.77 44.95 44.95 44.95
westbridge crossov... - - 10.86 - -
westbridge crossov... 2.00 - - - 9.17
westbridge crossov... - - - 9.22 -
westbridge crossov... - 6.86 - - -
franklin india sma... - 1.36 1.22 1.74 1.60
westbridge crossov... - - - - -
invesco oppenheime... - - - - -
invesco oppenheime... 3.07 - - - -
uti - equity fund - 2.73 2.88 2.77 2.84
mirae asset emergi... - 2.48 2.35 1.35 1.65
uti flexi cap fund 2.06 - - - -
om prakash manchan... 1.45 1.69 1.73 1.73 1.73
lo funds - emergin... - 1.04 - 1.50 1.48
life insurance cor... 1.48 - - - -
wasatch emerging i... - - - - -
al mehwar commerci... 1.06 - - - -
al mehwar commerci... - - - - -
first state invest... - - 1.04 - -
al mehwar commerci... - - - - -
llp 0.07 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Dr. Lal PathLabs submits analyst meet intimation27 Mar 2023, 2:44PM Dr. Lal PathLabs informs about institutional investor meeting23 Mar 2023, 10:41AM Dr. Lal PathLabs informs about resignation of company secretary 21 Mar 2023, 1:14PM Dr. Lal PathLabs informs about analyst meet 17 Mar 2023, 10:45AM Dr. Lal PathLabs selects Kyndryl to manage IT infrastructure stack15 Mar 2023, 3:08PM Dr. Lal PathLabs informs about analyst meet 15 Mar 2023, 9:54AM Dr. Lal PathLabs informs about analyst meet 2 Mar 2023, 3:12PM Dr. Lal PathLabs informs about analyst meet 23 Feb 2023, 12:31PM Dr. Lal PathLabs informs about analyst meet 17 Feb 2023, 10:09AM Dr. Lal PathLabs informs about analyst meet7 Feb 2023, 3:17PM Dr. Lal PathLabs informs about institutional investor meeting6 Feb 2023, 4:58PM Dr. Lal Pathlabs - Quaterly Results2 Feb 2023, 2:16PM Dr. Lal Pathlabs - Quaterly Results2 Feb 2023, 2:16PM Dr. Lal Pathlabs - Quaterly Results2 Feb 2023, 2:16PM Dr. Lal Pathlabs’ arm gets nod to acquire further 10% stake in APRL PathLabs31 Jan 2023, 10:00AM Dr. Lal PathLabs informs about analyst meet intimation27 Jan 2023, 3:04PM Dr. Lal PathLabs informs about closure of trading window28 Dec 2022, 3:59PM Dr. Lal PathLabs informs about analyst meet 7 Dec 2022, 5:09PM Dr. Lal PathLabs informs about analyst meet5 Dec 2022, 3:23PM Dr Lal PathLabs informs about disclosure 23 Nov 2022, 11:02AM Dr. Lal PathLabs informs about analyst meet 21 Nov 2022, 10:51AM Dr. Lal PathLabs informs about newspaper advertisement9 Nov 2022, 3:44PM Dr. Lal Pathlabs - Quaterly Results8 Nov 2022, 2:12PM Dr. Lal Pathlabs - Quaterly Results8 Nov 2022, 2:12PM Dr. Lal Pathlabs - Quaterly Results8 Nov 2022, 2:12PM Dr. Lal PathLabs informs about board meeting1 Nov 2022, 10:57AM Dr. Lal PathLabs informs about investor meeting19 Sep 2022, 10:28AM Dr. Lal PathLabs informs about analyst meet16 Sep 2022, 3:05PM Dr. Lal PathLabs informs about analyst meet29 Aug 2022, 1:09PM Dr. Lal Pathlabs informs about analyst meet22 Aug 2022, 10:03AM Dr. Lal Pathlabs informs about analyst meet17 Aug 2022, 12:54PM Dr. Lal Pathlabs reports 56% fall in Q1 consolidated net profit29 Jul 2022, 5:22PM Dr. Lal PathLabs informs about investor presentation 28 Jul 2022, 3:20PM Dr. Lal Pathlabs - Quaterly Results28 Jul 2022, 1:14PM Dr. Lal Pathlabs - Quaterly Results28 Jul 2022, 1:14PM Dr. Lal Pathlabs - Quaterly Results28 Jul 2022, 1:14PM Dr. Lal PathLabs informs about closure of trading window29 Jun 2022, 12:54PM Dr. Lal Pathlabs informs about analyst meet16 Jun 2022, 12:26PM Dr. Lal Pathlabs informs about newspaper advertisements9 Jun 2022, 12:16PM Dr. Lal PathLabs informs about AGM7 Jun 2022, 2:48PM Dr. Lal PathLabs informs about newspaper publication4 Jun 2022, 12:23PM Dr. Lal Pathlabs informs about analyst meet2 Jun 2022, 4:50PM Dr Lal Pathlabs informs about related party transactions28 May 2022, 3:39PM Dr. Lal PathLabs informs about transcript of conference call23 May 2022, 4:55PM Dr. Lal PathLabs informs about analyst meet23 May 2022, 2:06PM Dr. Lal Pathlabs reports 27% fall in Q4 consolidated net profit18 May 2022, 3:15PM Dr. Lal Pathlabs - Quaterly Results17 May 2022, 3:46PM Dr. Lal Pathlabs - Quaterly Results17 May 2022, 3:46PM Dr. Lal Pathlabs - Quaterly Results17 May 2022, 3:46PM Dr. Lal PathLabs informs about analyst meet 9 May 2022, 3:44PM

Dr. Lal Pathlabs Stock Price Analysis and Quick Research Report. Is Dr. Lal Pathlabs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Lal Pathlabs and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 423.81 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Lal Pathlabs has a Debt to Equity ratio of 0.2434 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Lal Pathlabs , the EPS growth was 22.829980956915 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Lal Pathlabs has OPM of 27.2449065683562 % which is a good sign for profitability.
     
  • ROE: Dr. Lal Pathlabs have a healthy ROE of 26.5032657837226 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Dr. Lal Pathlabs

X